Our results are in accordance with a recently published phase III randomized trial, SAFIA trial, in which neoadjuvant fulvestrant with or without palbociclib was given in patients with low-risk ER+ HER2– breast cancer, and no difference in pCR rate was observed (29). This evidence concerns the gene ESR1 and breast carcinoma.